New Triple-Threat treatment tested for Tough-to-Treat colon cancer
NCT ID NCT06967155
Summary
This study is testing whether a combination of three drugs (irinotecan, dabrafenib, and trametinib) plus a targeted antibody (cetuximab or panitumumab) can help control advanced colorectal cancer that has spread and carries a specific BRAF gene mutation. It is for patients whose first treatment has stopped working. The main goal is to see if this combination shrinks tumors and is safe for up to 3 years of monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blokhin's Russian Cancer Research Center
Moscow, Moscow, 115478, Russia
Conditions
Explore the condition pages connected to this study.